Arzneimittelwerk Dresden Gmbh

Resprotect Gmbh

Arzneimittelerk Dresden G.m.b.h.

Dieter Lohmann

Reni Bartsch

Hildegard Poppe

Hans-Joachim Jansch

Helmut Wunderlich

Natalja V Kaverina

Valentin V Lyskovzev

Angelika Rostock

Wolfgang Sauer

Volker Hagen

Ingrid Wielop

Gunter Reck

Andreas Stark

Christine Siegemund

Lothar Zenker

Anna N Grizenko

Aleksandr P Skoldinov

Hans-Joachim Heidrich

Brigitte Gentsch

Gottfried Faust

Helmut Vieweg

Alexandr P Skoldinov

Rudolf Fahrig

Siegfried Leistner

Jorg-Christian Heinrich

Joerg-Christian Heinrich

Lothar Zenkar

Ekaterina K Grigoreva

Angela Siegling

Andreas Rolfs

Herwart Ambrosius

Gunter Laban

Gunther Wagner

Karl Drossler

Michael Gutschow

Thomas Strohscheidt

Ilmira C Rachmankulova

Henrik Dieks

Tatjana A Voronina

Carla Ruger

Oleg M Glozman

Artur V Valdman

Taisija L Garibova

Larisa M Mescerjakova

Arkadij M Lichoserstov

Sergej B Seredenin

Yekaterina K Grigoryeva

Ljudmila A Zmurenko

Grigorij G Rozancev

Janek Teubner

Yekaterina A Talmachova

Gennadi G Chichkanov

Alwina W Stawrowskaya

Jörg-Christian Heinrich

The invention relates to special nucleosides, for example, a nucleoside of the formula I, wherein R-Rare as described herein, and also to drugs which contain these nucleosides. Furthermore, the invention relates to the use of such nucleosides in a method for suppressing or reducing the formation of resistance in the case of cytotstatic treatment of a cancer patient.

Nucleosides for suppressing or reducing the development of resistance in cytostatic therapy

The invention is directed to N-acetyl-4-phenyl-pyrrolidin-2-ones, which, because of their pronounced cerebroprotective effect in human medicine, can be used for the prophylaxis and treatment of cerebral functional disorders. Pursuant to the invention, these compounds are synthesized by reacting 4-phenyl-pyrrolidin-2-ones with a reactive derivative of a carboxylic acid, or by cyclizing N-acylaminobutyric acid derivatives.

N-acyl-4-phenyl-pyrrolidin-2-ones and method for preparing

A compound or its tautomer of Formula I, ##STR1## wherein R.sup.1 is hydrogen, a 6-methyl, 6-fluoro, 6-chloro, 6-bromo, or 6,7-dimethoxy residue,

3-(mercaptoalkyl)quinazoline

A method for preparing high bulk density crystalline 3-cyano-2-morpholino-5-(pyrid-4-yl)-pyridine which comprises precipitating a high bulk density crystalline 3-cyano-2-morpholino-5-(pyrid-4-yl)-pyridine from a starting material that is

Method for making high bulk density crystalline

5-(w-Aminoacyl)-5,10-dihydro-11H-dibenzo(b,e)(1,4)-diazepine-11-ones, and their preparation are disclosed for treatment of antiarrhythmia and as an anticholinergic drug.

5-(1-aminoacyl)-5,10-dihydro-11H-dibenzo[b,e](1,4)diazepin-11-ones

A method for preparing high bulk density crystalline 3-cyano-2-morpholino-5-(pyrid-4-yl)-pyridine which comprises precipitating a high bulk density crystaline 3-cyano-2-morpholino-5-(pyrid-4-yl)-pyridine from a starting material that is

High bulk density, crystalline

New 3-carbalkoxyamino-5-(alpha-aminopropionyl)-5H-dibenz[b,f]azepines of formula I and their pharmaceutically acceptable salts were found to be suitable actives for the treatment of cardiac arrhythmia. Previously unknown 3-carbalkoxyamino-5-(alpha-halogenpropionyl)-5H-dibenz[b,f]azepines are obtained from 3-carbalkoxyamino-5H-dibenz[b,f]azepines by reaction with alpha-halogenpropionyl halides. Through their reaction with ammonia, primary amines or secondary amines, the new 3-carbalkoxyamino-5-(alpha-aminopropionyl)-5H-dibenz[b,f]azepines are obtained, which can be optionally converted into their pharmaceutically acceptable acid addition salts.

3-carbalkoxyamino-5-(alpha-aminopropionyl)-5H-dibenz[b,f]azepines and

The substituted 5-(phenoxyalkanoylamino)-uracil compounds have the following formula I: ##STR1## wherein R.sub.1 and R.sub.2 are each independently hydrogen; a branched or linear alkyl group having 1 to 6 carbon atoms; a branched or straight chain alkenyl or alkynyl group having 1 to 6 carbons atoms; a cycloalkyl group having from 3 to 7 carbon atoms or a cycloalkylmethyl group having a cycloalkyl residue of 3 to 7 carbon atoms; or a phenylalkyl group having an alkyl residue having from 1 to 3 carbon atoms and a phenyl residue, the phenyl residue being unsubstituted or having a halogen, methoxy, methyl or trifluoromethyl substituent; R.sub.3 is a hydrogen, methyl or amino groups; R.sub.4 is halogen, methoxy or methyl groups, and n is 1 or 2. Pharmaceutical compositions for treating cerebrovascular, neuronal-degenerative and senility-induced disorders associated with learning, memory and cognitive dysfunctions are described which contain a therapeutically effective amount of the substituted 5-(phenoxyalkanoylamino)-uracil in a pharmaceutically acceptable carrier.

Substituted 5-(phenoxyalkanoylamino)-uracil compounds, methods for

New 3-carbalkoxyamino-5-aminoacyl-5H-dibenz[b,f]azepines and their pharmaceutically acceptable acid addition salts, and methods for their synthesis are described. These compounds are useful as antiarrhythmic agents in the treatment of heart disorders. The new compounds are made by reacting a 3-carbalkoxyamino-5-halogenacyl-5H-dibenz[b,f]azepines with an amine to form the desired target product, which can be optionally converted into its pharmaceutically acceptable acid addition salt.

3-carbalkoxyamino-5-aminoacyl-5H-dibenz[b,f]azepines, and methods for

Growing community of inventors

Radebeul, Germany

Dieter Lohmann